Jazz Pharmaceuticals plc (JAZZ) Financials
JAZZ Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 11.2 billion | 7.7 billion |
2023-06-30 | 11.3 billion | 7.7 billion |
2023-03-31 | 11.0 billion | 7.7 billion |
2022-12-31 | 10.8 billion | 7.7 billion |
JAZZ Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | 302.9 million | 56.1 million |
2023-06-30 | 291.0 million | 61.4 million |
2023-03-31 | 315.9 million | 56.4 million |
2022-12-31 | -42.4 million | 61.6 million |
JAZZ Net Income
Graph available only for supporters. Become a supporter to see it.
Date | Net Income |
---|---|
2023-09-30 | 146.8 million |
2023-06-30 | 104.4 million |
2023-03-31 | 69.4 million |
2022-12-31 | -240.7 million |
JAZZ Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 1.6 billion | - | 78.6 million |
2023-06-30 | 1.4 billion | 5.7 billion | 82.5 million |
2023-03-31 | 1.2 billion | 5.7 billion | 72.1 million |
2022-12-31 | 881.5 million | 5.7 billion | 87.8 million |
JAZZ Shares Outstanding
JAZZ Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 4.3 million | 234.4 million | 308.3 million | - |
2023-06-30 | 5.7 million | 209.2 million | 340.8 million | - |
2023-03-31 | 4.8 million | 189.4 million | 297.9 million | - |
2022-12-31 | 384.4 million | 172.6 million | 383.2 million | - |
JAZZ Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 972.1 million | 102.2 million |
2023-06-30 | 957.3 million | 97.5 million |
2023-03-31 | 892.8 million | 128.6 million |
2022-12-31 | 972.1 million | 167.4 million |
JAZZ
Price: $110.31
52 week price:
Payout Ratio Range:
Earnings Per Share: 6.10 USD
P/E Ratio: 144.80
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 468012
Ebitda: 136.8 millionMarket Capitalization: 7.3 billion